能否靶向T细胞急性淋巴细胞白血病？
Can one target T-cell ALL?
作者信息
Ferrando Adolfo
机构信息
Institute for Cancer Genetics, Columbia University, 1130 St Nicholas Ave., ICRC 401B, New York, NY, 10032, USA.
出版信息
Best Pract Res Clin Haematol. 2018 Dec;31(4):361-366. doi: 10.1016/j.beha.2018.10.001. Epub 2018 Oct 17.
Abstract
Progress in our understanding of the central genes, pathways, and mechanisms in the pathobiology of T-cell acute lymphoblastic leukemia (T-ALL) has identified key drivers of the disease, opening new opportunities for therapy. Drugs targeting highly prevalent genetic alterations in NOTCH1 and CDKN2A are being explored, and multiple other targets with readily available therapeutic agents, and immunotherapies are being investigated. The molecular basis of T-ALL is reviewed here and potential targets and therapeutic targets discussed.
摘要
我们对T细胞急性淋巴细胞白血病（T-ALL）病理生物学中的核心基因、信号通路和机制的理解取得了进展，已确定了该疾病的关键驱动因素，为治疗带来了新机遇。针对NOTCH1和CDKN2A中高度普遍的基因改变的药物正在探索中，其他多种有现成治疗药物的靶点以及免疫疗法也在研究中。本文综述了T-ALL的分子基础，并讨论了潜在靶点和治疗靶点。
相似文献
1
Can one target T-cell ALL?
Best Pract Res Clin Haematol. 2018 Dec;31(4):361-366. doi: 10.1016/j.beha.2018.10.001. Epub 2018 Oct 17.
2
In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
Haematologica. 2008 Apr;93(4):533-42. doi: 10.3324/haematol.11894. Epub 2008 Mar 5.
3
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16.
4
Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia.
Blood. 2009 Nov 12;114(20):4451-9. doi: 10.1182/blood-2009-07-233346. Epub 2009 Sep 16.
5
The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Haematologica. 2016 Sep;101(9):1010-7. doi: 10.3324/haematol.2016.146381.
6
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Cancer Res. 2009 Apr 1;69(7):3060-8. doi: 10.1158/0008-5472.CAN-08-4295. Epub 2009 Mar 24.
7
More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
Oncologist. 2021 Feb;26(2):e298-e305. doi: 10.1002/onco.13595. Epub 2020 Nov 26.
8
PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
J Hematol Oncol. 2021 Jun 24;14(1):97. doi: 10.1186/s13045-021-01114-1.
9
Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
Nat Commun. 2021 May 4;12(1):2507. doi: 10.1038/s41467-021-22787-9.
10
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Blood. 2009 Jun 11;113(24):6172-81. doi: 10.1182/blood-2008-02-136762. Epub 2009 Feb 26.
引用本文的文献
1
PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL.
NPJ Precis Oncol. 2024 Jul 20;8(1):152. doi: 10.1038/s41698-024-00638-2.
2
Identifying Candidate Gene Drivers Associated with Relapse in Pediatric T-Cell Acute Lymphoblastic Leukemia Using a Gene Co-Expression Network Approach.
Cancers (Basel). 2024 Apr 25;16(9):1667. doi: 10.3390/cancers16091667.
3
Targeted Treatment and Immunotherapy in High-risk and Relapsed/ Refractory Pediatric Acute Lymphoblastic Leukemia.
Curr Pediatr Rev. 2023;19(2):150-156. doi: 10.2174/1573396318666220901165247.
4
NOTCH-ing up nucleotide metabolism in T-cell acute lymphoblastic leukemia.
Commun Biol. 2021 Jun 29;4(1):809. doi: 10.1038/s42003-021-02330-8.
5
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2021 Apr 26;22(9):4502. doi: 10.3390/ijms22094502.
6
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia.
Exp Hematol Oncol. 2020 Nov 13;9(1):31. doi: 10.1186/s40164-020-00187-x.
7
New Drug Repositioning Candidates for T-ALL Identified Human/Murine Gene Signature Comparison.
Front Oncol. 2020 Nov 9;10:557643. doi: 10.3389/fonc.2020.557643. eCollection 2020.
8
More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
Oncologist. 2021 Feb;26(2):e298-e305. doi: 10.1002/onco.13595. Epub 2020 Nov 26.
9
Genetic Heterogeneity of Esophageal Squamous Cell Carcinoma with Inherited Family History.
Onco Targets Ther. 2020 Sep 3;13:8795-8802. doi: 10.2147/OTT.S262512. eCollection 2020.
10
Single-cell DNA amplicon sequencing reveals clonal heterogeneity and evolution in T-cell acute lymphoblastic leukemia.
Blood. 2021 Feb 11;137(6):801-811. doi: 10.1182/blood.2020006996.
本文引用的文献
1
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Cancer Cell. 2018 Jul 9;34(1):136-147.e6. doi: 10.1016/j.ccell.2018.06.003.
2
The presence of mutated and deleted PTEN is associated with an increased risk of relapse in childhood T cell acute lymphoblastic leukaemia treated with AIEOP-BFM ALL protocols.
Br J Haematol. 2018 Sep;182(5):705-711. doi: 10.1111/bjh.15449. Epub 2018 Jun 25.
3
An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
Leukemia. 2018 Sep;32(9):1970-1983. doi: 10.1038/s41375-018-0065-5. Epub 2018 Feb 20.
4
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Nature. 2018 Jan 25;553(7689):511-514. doi: 10.1038/nature25186. Epub 2018 Jan 17.
5
Targeted cellular immunotherapy for T cell malignancies.
Nat Med. 2017 Dec 7;23(12):1402-1403. doi: 10.1038/nm.4458.
6
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Blood. 2018 Jan 25;131(4):421-425. doi: 10.1182/blood-2017-07-797597. Epub 2017 Nov 29.
7
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies.
Nat Med. 2017 Dec;23(12):1416-1423. doi: 10.1038/nm.4444. Epub 2017 Nov 13.
8
Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and fusion: A case report.
Exp Ther Med. 2017 Nov;14(5):3979-3984. doi: 10.3892/etm.2017.5046. Epub 2017 Aug 28.
9
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Leukemia. 2018 Mar;32(3):788-800. doi: 10.1038/leu.2017.276. Epub 2017 Aug 30.
10
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.
Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3.
Zotero 插件